{
    "nctId": "NCT01302002",
    "briefTitle": "The Use of Metformin in Early Breast Cancer Patients Pre-Surgery",
    "officialTitle": "The Use of Metformin in Early Breast Cancer Patients Pre-Surgery: A Phase 0 Study Regarding The Biological Effect",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "To determine the in situ effects of metformin in women with operable stage I or II breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Invasive breast cancer T1 or T2, Nx\n* Knowledge of the investigational nature of the study and ability to provide consent for study participation\n\nExclusion Criteria:\n\n* Diabetes or baseline glucose or Glycosylated haemoglobin upper limit of normal for the institution\n* Recent use of corticosteroids\n* AST \\> 1.5 times upper limit of normal for the institution\n* Pregnancy\n* Serious clinical illness\n* Prior or concurrent systemic neoadjuvant Breast Cancer therapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}